The Asia Pacific brain aneurysm treatment market is expected to reach US$ 1,737.32 million by 2027 from US$ 576.71 million in 2019. The market is estimated to grow at a CAGR of 14.9% from 2020 to 2027.
The growth of the Asia Pacific brain aneurysm treatment market is attributed to the rise in research activities, increasing prevalence of brain aneurysm, and growing number of product launches. However, the high cost of procedures hinders the growth of the market.
The prevalence of brain aneurysms is rising in many Asian countries due to the growing prevalence of cerebrovascular disease, as well as an aging population. As per the Ministry of Health, Labor, and Welfare 2017 Survey, the number of patients suffering from cerebrovascular diseases, including subarachnoid hemorrhages and brain infarctions, was estimated to be over 1.1 million in Japan. Geriatric population is at high risk of developing brain aneurysm and other associated diseases. The rising elderly population is estimated to develop growing incidences for brain injuries and other neurovascular disorders.
The Asia Pacific brain aneurysm treatment market, based on type, is segmented into surgery and medication. In 2019, the medication segment held a larger share of the market; however, the surgery segment is expected to register a higher CAGR in the market during the forecast period. The Asia Pacific brain aneurysm treatment market, based on condition, is segmented into unruptured aneurysm and ruptured aneurysm. In 2019, the unruptured aneurysm segment held a larger share of the market; however, the ruptured aneurysm segment is expected to register a higher CAGR during 2020-2027. Furthermore, the Asia Pacific brain aneurysm treatment market, based on end user, is segmented into hospitals and clinics. In 2019, the hospitals segment held a larger share of the market; however, the market for the clinics segment is expected to grow at a higher CAGR during the forecast period.
A few major primary and secondary sources referred to in the process of preparing the report on the brain aneurysm treatment market are the World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.
Reasons to Buy:
The growth of the Asia Pacific brain aneurysm treatment market is attributed to the rise in research activities, increasing prevalence of brain aneurysm, and growing number of product launches. However, the high cost of procedures hinders the growth of the market.
The prevalence of brain aneurysms is rising in many Asian countries due to the growing prevalence of cerebrovascular disease, as well as an aging population. As per the Ministry of Health, Labor, and Welfare 2017 Survey, the number of patients suffering from cerebrovascular diseases, including subarachnoid hemorrhages and brain infarctions, was estimated to be over 1.1 million in Japan. Geriatric population is at high risk of developing brain aneurysm and other associated diseases. The rising elderly population is estimated to develop growing incidences for brain injuries and other neurovascular disorders.
The Asia Pacific brain aneurysm treatment market, based on type, is segmented into surgery and medication. In 2019, the medication segment held a larger share of the market; however, the surgery segment is expected to register a higher CAGR in the market during the forecast period. The Asia Pacific brain aneurysm treatment market, based on condition, is segmented into unruptured aneurysm and ruptured aneurysm. In 2019, the unruptured aneurysm segment held a larger share of the market; however, the ruptured aneurysm segment is expected to register a higher CAGR during 2020-2027. Furthermore, the Asia Pacific brain aneurysm treatment market, based on end user, is segmented into hospitals and clinics. In 2019, the hospitals segment held a larger share of the market; however, the market for the clinics segment is expected to grow at a higher CAGR during the forecast period.
A few major primary and secondary sources referred to in the process of preparing the report on the brain aneurysm treatment market are the World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific brain aneurysm treatment market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific brain aneurysm treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
3. Research Methodology
4. Brain Aneurysm Treatment - Market Landscape
5. Asia Pacific Brain Aneurysm Treatment Market - Industry Dynamics
6. Brain Aneurysm Treatment Market - Regional Analysis
7. Brain Aneurysm Treatment Market Analysis - By Type
8. Brain Aneurysm Treatment Market - By Condition
9. Brain Aneurysm Treatment Market - By End User
10. Brain Aneurysm Treatment Market- Regional Analysis
11. Impact of COVID-19 Pandemic on Asia Pacific Brain Aneurysm Treatment Market
12. Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Stryker Corporation
- MicroPort Scientific Corporation
- Terumo Corporation
- KANEKA CORPORATION
- Mizuho Medical Co,Ltd.
